放射性核素诊疗现状与未来展望

罗亚平; 李方

doi:10.12290/xhyxzz.2023-0236

放射性核素诊疗现状与未来展望

doi: 10.12290/xhyxzz.2023-0236

罗亚平,
李方^,

中国医学科学院北京协和医院核医学科，北京 100730

详细信息

通讯作者:
李方, E-mail: lifang@pumch.cn

中图分类号: R445.5;R-1
计量
- 文章访问数: 1695
- HTML全文浏览量: 39
- PDF下载量: 289
- 被引次数: 0
出版历程
- 收稿日期: 2023-05-14
- 录用日期: 2023-07-18
- 网络出版日期: 2023-07-20
- 刊出日期: 2023-07-30

Current Status and Future Prospects of Theranostics with Radiopharmaceuticals

LUO Yaping,
LI Fang^,

Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information

Corresponding author: LI Fang, E-mail: lifang@pumch.cn

摘要

摘要: 放射性核素诊疗(即核医学技术)是利用放射性核素进行疾病诊断和治疗的技术，其已历经百余年发展历程。得益于设备和放射性药物的进步、临床需求的增加、国家政策的支持以及全球化合作的开启，核医学技术得以快速发展。时至今日，核医学技术已成为一种广泛应用于影像诊断及治疗的技术，在临床中发挥重要且独特的价值。未来，核医学仍将在影像诊断、放射性核素治疗、人工智能领域继续蓬勃发展，并将取得更大的进步。
- 放射性核素 /
- 诊疗 /
- 核医学
Abstract: Nuclear medicine is a novel technique of theranostics that uses radiopharmaceuticals. Nuclear medicine dated back to a century ago. Owing to the development of nuclear medicine devices and radiopharmaceuticals, increasing clinical demand, government support, and global cooperations, nuclear medicine has witnessed a rapid development. Nowadays, nuclear medicine has played an important and unique role in diagnosis and therapy. There are opportunities and challenges in future development of nuclear medicine, and more progress will be made in nuclear medicine imaging, radionuclide therapy, and artificial intelligence.
- radiopharmaceuticals /
- theranostics /
- nuclear medicine
注释:

作者贡献：罗亚平负责文献查阅、论文撰写及修订；李方负责选题设计及论文指导。

利益冲突：所有作者均声明不存在利益冲突

HTML全文

参考文献(20)

[1]	Carlsson S. A glance at the history of nuclear medicine[J]. Acta Oncol, 1995, 34: 1095-1102. doi: 10.3109/02841869509127236
[2]	Middlebrooks JT. A Half-Century of Nuclear Medicine[J]. J Nucl Med Technol, 2020, 48: 40S-42S. doi: 10.2967/jnmt.119.233486
[3]	Hutton BF. The origins of SPECT and SPECT/CT[J]. Eur J Nucl Med Mol Imaging, 2014, 41: S3-S16. doi: 10.1007/s00259-013-2606-5
[4]	Verburg FA, Heinzel A, Hänscheid H, et al. Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 199-201. doi: 10.1007/s00259-013-2609-2
[5]	Zimmerman RE. Gamma cameras-state of the art[J]. Med Instrum, 1979, 13: 161-164.
[6]	Wagner HN Jr. A brief history of positron emission tomography (PET)[J]. Semin Nucl Med, 1998, 28: 213-220. doi: 10.1016/S0001-2998(98)80027-5
[7]	Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. doi: 10.1056/NEJMoa1607427
[8]	Fallah J, Agrawal S, Gittleman H, et al. FDA Approval Summary: Lutetium Lu(177) Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer[J]. Clin Cancer Res, 2023, 29: 1651-1657. doi: 10.1158/1078-0432.CCR-22-2875
[9]	Luster M, Aktolun C, Amendoeira I, et al. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium[J]. Thyroid, 2019, 29: 7-26. doi: 10.1089/thy.2017.0129
[10]	Singh S, Hope TA, Bergsland EB, et al. Consensus Report of the 2021 National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting[J]. J Natl Cancer Inst, 2023. doi: 10.1093/jnci/djad096.
[11]	Ferretti S, Mercinelli C, Marandino L, et al. Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs[J]. Res Rep Urol, 2023, 15: 243-259.
[12]	Otte A, van de Wiele C, Dierckx RA. Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step[J]. Nucl Med Commun, 2009, 30: 5-15. doi: 10.1097/MNM.0b013e328313e565
[13]	Voutsinas N, Lekperic S, Barazani S, et al. Treatment of Primary Liver Tumors and Liver Metastases, Part 1: Nuclear Medicine Techniques[J]. J Nucl Med, 2018, 59: 1649-1654. doi: 10.2967/jnumed.116.186346
[14]	Velikyan I. Prospective of (68)Ga-radiopharmaceutical development[J]. Theranostics, 2013, 4: 47-80.
[15]	Velikyan I. Continued rapid growth in (68) Ga applications: update 2013 to June 2014[J]. J Labelled Comp Radiopharm, 2015, 58: 99-121. doi: 10.1002/jlcr.3250
[16]	Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer[J]. N Engl J Med, 2021, 385: 1091-1103. doi: 10.1056/NEJMoa2107322
[17]	Cheng X, Li F, Liang L. Boron Neutron Capture Therapy: Clinical Application and Research Progress[J]. Curr Oncol, 2022, 29: 7868-7886. doi: 10.3390/curroncol29100622
[18]	Yordanova A, Ahmadzadehfar H. Combination Therapies with PRRT[J]. Pharmaceuticals (Basel), 2021, 14: 1005. doi: 10.3390/ph14101005
[19]	Nensa F, Demircioglu A, Rischpler C. Artificial Intelligence in Nuclear Medicine[J]. J Nucl Med, 2019, 60: 29S-37S. doi: 10.2967/jnumed.118.220590
[20]	Seifert R, Weber M, Kocakavuk E, et al. Artificial Intelligence and Machine Learning in Nuclear Medicine: Future Perspectives[J]. Semin Nucl Med, 2021, 51: 170-177. doi: 10.1053/j.semnuclmed.2020.08.003

施引文献

资源附件(0)

访问统计

点击查看大图

计量

文章访问数: 1695
HTML全文浏览量: 39
PDF下载量: 289
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

地址：	北京市东城区帅府园1号北京协和医院老楼7号楼 3层302室《协和医学杂志》编辑部
电话：	010-69154261/4262
E - mail：	medj@pumch.cn mjpumch@126.com
期刊网站版权所有：	《协和医学杂志》编辑部京ICP备 11002662

留言板

放射性核素诊疗现状与未来展望

doi: 10.12290/xhyxzz.2023-0236

通讯作者:
李方, E-mail: lifang@pumch.cn

计量

Current Status and Future Prospects of Theranostics with Radiopharmaceuticals

Corresponding author: LI Fang, E-mail: lifang@pumch.cn

计量

目录

留言板

放射性核素诊疗现状与未来展望

doi: 10.12290/xhyxzz.2023-0236

通讯作者: 李方, E-mail: lifang@pumch.cn

计量

出版历程

Current Status and Future Prospects of Theranostics with Radiopharmaceuticals

Corresponding author: LI Fang, E-mail: lifang@pumch.cn

计量

出版历程

目录

通讯作者:
李方, E-mail: lifang@pumch.cn